Journal: Cancer cell

Article Title: Taxanes trigger cancer cell killing in vivo by inducing non-canonical T cell cytotoxicity.

doi: 10.1016/j.ccell.2023.05.009

Figure Lengend Snippet: Figure 5. Pre-clinical assessment of the therapeutic benefits of T cells pre-treated with docetaxel (A) Representative images and quantification of cleaved-caspase 3 (CC3) immunofluorescent staining in MMTV-PyMT organoids expressing OVA and co- cultured with T cells isolated from the spleen of OT I mice upon pre-treatment with a vehicle control or docetaxel. n = 3 biological repeats, scale bar = 100 mm. Data are presented as mean ± SEM, p values were determined using unpaired, nonparametric t-test with a Mann-Whitney U correction in GraphPad Prism. (B) Schematic representation of experiment design. (C and D) Tumor growth in mice bearing KB1P tumors (C) or MMTV-PyMT tumors (D) and transplanted with CD4+ T cells pre-treated in vitro with a vehicle control or with docetaxel. For Figure 5C, the p value was determined in R using a linear mixed-effects model, for Figure 5D, due to the lower number of animals, the p value was determined in Prism GraphPad using a mixed-effects analysis with a Geisser-Greenhouse correction. (E and F) Kaplan-Meier analysis of survival from time of T cell transfer in mice bearing KB1P tumors (E) or MMTV-PyMT tumors (F) transplanted with CD4+ T cells pre-treated in vitro with a vehicle control or with docetaxel. For E and F, p = values were determined using a log rank Mantel-Cox test in GraphPad Prism. See also Figure S5, Tables S1, and S2.

Article Snippet: Vehicle for cyclophosphamide: saline; vehicle for doxorubicin: saline; vehicle for docetaxel: acetonitrile containing 0.1% acetic acid. d IgG treatment: on day 1, day 3 and day 5 prior to treatment with vehicle control or with chemotherapy, treatment with 400 mg (day 1), or 200 mg (day 3 and day 5) per mouse with InVivoMAb rat IgG2b isotype control (BioXCell, clone LTF-2, Cat. No. BE0090). d aCD4 treatment: on day 1, day 3 and day 5 prior to treatment with vehicle control or with chemotherapy, treatment with 400 mg (day 1), or 200 mg (day 3 and day 5) per mouse with InVivoMAb anti-mouse CD4 (BioXCell, clone GK1.5, Cat. No. BE003-1). d aCD8 treatment: on day 1, day 3 and day 5 prior to treatment with vehicle control or with chemotherapy, treatment with 400 mg (day 1), or 200 mg (day 3 and day 5) permouse with InVivoMAb anti-mouse CD8 (BioXCell, clone YTS 169.4, Cat. No. BP0117).

Techniques: Staining, Expressing, Cell Culture, Isolation, Control, MANN-WHITNEY, In Vitro

Journal: Immunity

Article Title: TCR-independent CD137 (4–1BB) signaling promotes CD8 + -exhausted T cell proliferation and terminal differentiation

doi: 10.1016/j.immuni.2023.06.007

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Anti-mouse OX40 , Bio X Cell , Cat#: BE0031 RRID: AB_1107592.

Techniques: Purification, Recombinant, Lysis, Negative Control, Cell Isolation, Staining, Knock-Out, Isolation, Control, Infection, RNA Sequencing, Software, Gene Expression

Journal: eLife

Article Title: Single-cell glycomics analysis by CyTOF-Lec reveals glycan features defining cells differentially susceptible to HIV

doi: 10.7554/eLife.78870

Figure Lengend Snippet:

Article Snippet: Antibody , Anti-Human CD134/OX40 (ACT35) (Mouse, Monoclonal) , Fluidigm , Cat# 3158012B , CyTOF (1:25).

Techniques: Recombinant, Plasmid Preparation, Software

Journal: iScience

Article Title: Defects in NK cell immunity of pediatric cancer patients revealed by deep immune profiling

doi: 10.1016/j.isci.2024.110837

Figure Lengend Snippet:

Article Snippet: Anti-OX40 (clone ACT35, conjugated to 150Nd) , Standard BioTools , Cat#3150023B.

Techniques: Purification, Clinical Proteomics, Recombinant, Blocking Assay, Staining, Saline, Mass Cytometry, Software, Cytometry

Journal: bioRxiv

Article Title: Novel APC-like properties of human NK cells directly regulate T cell activation

doi: 10.1101/016816

Figure Lengend Snippet: (A) ANK cells (1 × 10 6 ) were incubated with recombinant HA or BSA proteins (0.5 μg/ml) and pooled anti- HA or control sera (1 μl per well), for 180 minutes at 37C. The cells were subsequently stained for surface expression of CD16. MFI levels are indicated for CD16 − (upper left corner) and CD16 + NK cells (upper right corner). (B) The proliferative response of 5 × 10 4 OFR3 clone T cells to different concentrations of HA or BSA proteins, in the presence of a fixed concentration of pooled anti-HA or control sera (1 μl per well). Irradiated ANK cells (1 × 10 5 ) were used as APCs. The cells were cultured for 48 hours and pulsed with [ 3 H]thymidine for the last 24 hours. Values are mean ± SD for triplicate samples. Prior to harvesting, 100 μl of supernatant was taken up for ELISA measurement of IL-2 and IFN-γ. Data are representative of 3 separate experiments. In vivo expression of MHC class II and costimulatory molecules on human NK cells. We next sought to characterize the in vivo regulation of MHC class II and costimulatory molecules on human NK cells. We isolated NK cells from inflamed tonsils obtained from 4 donors who underwent elective tonsillectomies. Interestingly, NK cells derived from all samples displayed significant levels of HLA-DR,DP,DQ, CD86, CD70, OX40 ligand, and, less prominently, CD80 . These observations indicate that human NK cells acquire APC-like phenotype in vivo in inflamed lymphoid organs without any external manipulation.

Article Snippet: Anti- CD56 and anti-CD4 were obtained from DAKO Corp. Anti-CXCR3, anti-NKp30, and anti-NKG2D were obtained from R&D Systems Inc. Biotinylated anti–OX40 ligand mAb was obtained from MBL International Corp.

Techniques: Incubation, Recombinant, Staining, Expressing, Concentration Assay, Irradiation, Cell Culture, Enzyme-linked Immunosorbent Assay, In Vivo, Isolation, Derivative Assay